The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
Open accessAbstract
Purpose: Anaplastic oligodendrogliomas, pure (AO) and mixed (anaplastic oligoastrocytoma [AOA]), are chemosensitive, especially if codeleted for 1p/19q, but whether patients live longer after chemoradiotherapy is unknown. Patients and Methods: Eligible patients with AO/AOA were randomly assigned to procarbazine, lomustine, and vincristine (PCV) plus radiotherapy (RT) versus RT alone. The primary end point was overall survival (OS). Results: Two hundred ninety-one eligible patients were randomly assigned: 148 to PCV plus RT and 143 to RT. For the entire cohort, there was no difference in median survival by treatment (4.6 years for PCV plus RT v 4.7 years for RT; hazard ratio [HR] = 0.79; 95% CI, 0.60 to 1.04; P = .1). Patients with codeleted tumors lived longer than those with noncodeleted tumors (PCV plus RT: 14.7 v 2.6 years, HR = 0.36, 95% CI, 0.23 to 0.57, P < .001; RT: 7.3 v 2.7 years, HR = 0.40, 95% CI, 0.27 to 0.60, P < .001), and the median survival of those with codeleted tumors treated with PCV plus RT was twice that of patients receiving RT (14.7 v 7.3 years; HR = 0.59; 95% CI, 0.37 to 0.95; P = .03). For those with noncodeleted tumors, there was no difference in median survival by treatment arm (2.6 v 2.7 years; HR = 0.85; 95% CI, 0.58 to 1.23; P = .39). In Cox models that included codeletion status, the adjusted OS for all patients was prolonged by PCV plus RT (HR = 0.67; 95% CI, 0.50 to 0.91; P = .01). Conclusion: For the subset of patients with 1p/19q codeleted AO/AOA, PCV plus RT may be an especially effective treatment, although this observation was derived from an unplanned analysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Cairncross, J. G., Ueki, K., Zlatescu, M. C., Lisle, D. K., Finkelstein, D. M., Hammond, R. R., Silver, J. S., Stark, P. C., Macdonald, D. R., Ino, Y., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.19.1473 · Cited by 1,610
Wick, W., Hartmann, C., Engel, C., Stoffels, M., Felsberg, J., Stockhammer, F., Sabel, M. C., Koeppen, S., Ketter, R., Meyermann, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6497 · Cited by 809
Smith, J. S., Perry, A., Borell, T. J., Lee, H. K., O’Fallon, J., Hosek, S. M., Kimmel, D., Yates, A., Burger, P. C., Scheithauer, B. W., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.636 · Cited by 804
Self-citationvan den Bent, M. J., Carpentier, A. F., Brandes, A. A., Sanson, M., Taphoorn, M. J. B., Bernsen, H. J. J. A., Frenay, M., Tijssen, C. C., Grisold, W., Sipos, L., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.6078 · Cited by 748
Cairncross, G., Berkey, B., Shaw, E., Jenkins, R., Scheithauer, B., Brachman, D., Buckner, J., Fink, K., Souhami, L., Laperierre, N., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3414 · Cited by 728
Self-citationREIFENBERGER, J., Reifenberger, G., Liu, L., James, C. D., Wechsler, W., & Collins, V. P. (1994) · PubMed Central · Cited by 601
Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma
Bettegowda, C., Agrawal, N., Jiao, Y., Sausen, M., Wood, L. D., Hruban, R. H., Rodriguez, F. J., Cahill, D. P., McLendon, R., Riggins, G., et al. (2011) · Science · doi:10.1126/science.1210557 · Cited by 553
Cairncross, G., Macdonald, D., Ludwin, S., Lee, D., Cascino, T., Buckner, J., Fulton, D., Dropcho, E., Stewart, D., & Schold, C. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.10.2013 · Cited by 442
Self-citationHoang-Xuan, K., Capelle, L., Kujas, M., Taillibert, S., Duffau, H., Lejeune, J., Polivka, M., Crinière, E., Marie, Y., Mokhtari, K., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.169 · Cited by 356
Successful chemotherapy for recurrent malignant oligodendroglioma
Cairncross, J. G., & Macdonald, D. R. (1988) · Annals of Neurology · doi:10.1002/ana.410230408 · Cited by 344
Yip, S., Butterfield, Y. S., Morozova, O., Chittaranjan, S., Blough, M. D., An, J., Birol, I., Chesnelong, C., Chiu, R., Chuah, E., et al. (2012) · The Journal of Pathology · doi:10.1002/path.2995 · Cited by 307
van den Bent, M. J., Taphoorn, M. J. B., Brandes, A. A., Menten, J., Stupp, R., Frenay, M., Chinot, O., Kros, J. M., van der Rijt, C. C. D., Vecht, C. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.015 · Cited by 297
van den Bent, M. J., Kros, J. M., Heimans, J. J., Pronk, L. C., van Groeningen, C. J., Krouwer, H. G. J., Taphoorn, M. J. B., Zonnenberg, B. A., Tijssen, C. C., Twijnstra, A., et al. (1998) · Neurology · doi:10.1212/wnl.51.4.1140 · Cited by 206
Chinot, O.-L., Honore, S., Dufour, H., Barrie, M., Figarella-Branger, D., Muracciole, X., Braguer, D., Martin, P.-M., & Grisoli, F. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2449 · Cited by 179
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors
Lassman, A. B., Iwamoto, F. M., Cloughesy, T. F., Aldape, K. D., Rivera, A. L., Eichler, A. F., Louis, D. N., Paleologos, N. A., Fisher, B. J., Ashby, L. S., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor040 · Cited by 176
Influence of Unrecognized Molecular Heterogeneity on Randomized Clinical Trials
Betensky, R. A., Louis, D. N., & Gregory Cairncross, J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.140 · Cited by 167
Mackworth, N. H., Fobair, P., & Prados, M. (1992) · Journal of Neuro-Oncology · doi:10.1007/bf00172600 · Cited by 150
Update on molecular findings, management and outcome in low-grade gliomas
Bourne, T. D., & Schiff, D. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.159 · Cited by 146
Kim, L., Hochberg, F. H., Thornton, A. F., et al. (1996) · Journal of neurosurgery · doi:10.3171/jns.1996.85.4.0602 · Cited by 139
Successful chemotherapy for newly diagnosed aggressive oligodendroglioma
Macdonald, D., Gaspar, L. E., & Cairncross, J. G. (1990) · Annals of Neurology · doi:10.1002/ana.410270519 · Cited by 138
Survey of treatment recommendations for anaplastic oligodendroglioma
Abrey, L. E., Louis, D. N., Paleologos, N. A., Lassman, A. B., Raizer, J. J., Mason, W. P., Finlay, J. L., Macdonald, D. R., DeAngelis, L. M., & Cairncross, J. G. (2007) · Neuro-Oncology · doi:10.1215/15228517-2007-002 · Cited by 107
Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma
Paleologos, N. A., Macdonald, D. R., Vick, N. A., & Cairncross, J. G. (1999) · Neurology · doi:10.1212/wnl.53.5.1141 · Cited by 79
Wang, M., Cairncross, G. J., Shaw, E., Jenkins, R. B., Scheithauer, B. W., Brachman, D. G., Buckner, J. C., Fink, K., Souhami, L., Laperrière, N., et al. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.06.004 · Cited by 59
Self-citationInitial treatment patterns over time for anaplastic oligodendroglial tumors
Panageas, K. S., IWAMOTO, F. M., Cloughesy, T. F., Aldape, K., Rivera, A. L., Eichler, A. F., Louis, D. N., Paleologos, N. A., Fisher, B. J., Ashby, L., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos065 · Cited by 57
Cited by
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
The Cancer Genome Atlas Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402121 · Cited by 3,148
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
Weller, M., van den Bent, M., Preusser, M., Le Rhun, E., Tonn, J. C., Minniti, G., Bendszus, M., Balana, C., Chinot, O., Dirven, L., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00447-z · Cited by 2,048
Ostrom, Q. T., Patil, N., Cioffi, G., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa200 · Cited by 1,789
Ostrom, Q. T., Gittleman, H., Xu, J., Kromer, C., Wolinsky, Y., Kruchko, C., & Barnholtz-Sloan, J. S. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now207 · Cited by 1,204
Metadata
- Authors
- Cairncross, G., Wang, M., Shaw, E., Jenkins, R., Brachman, D., Buckner, J., Fink, K., Souhami, L., Laperriere, N., Curran, W., & Mehta, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-01-20
- Volume
- 31
- Issue
- 3
- Pages
- 337-343
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2147013683
- Cited by
- 1,156
- References
- 34
- FWCI
- 38.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.